Catalyst
Slingshot members are tracking this event:
Phase 2b interim safety data and patient immunology data on the A24 and A25 Human Leukocyte Antigen status due Q4 2016 for NeuVax in combination with Herceptin (trastuzumab) for breast cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GALE |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 10, 2016
Occurred Source:
http://investors.galenabiopharma.com/investors/press-releases/press-release-details/2016/Galena-Biopharma-to-Present-NeuVax-nelipepimut-S-plus-Trastuzumab-Interim-Safety-Data-at-the-European-Society-for-Medical-Oncology-ESMO-2016-Congress/default.aspx
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2b Interim Safety Data, Immunology Data, A24, A25, Human Leukocyte Antigen, Hla, Q4 2016, Neuvax, Herceptin, Breast Cancer, Trastuzumab
